Free Stock Report

Best Pharmaceutical Stocks ASX.

Our pharmaceutical stock research is curated by the Sharewise equity analyst and research team, reviewed and updated monthly as the markets move.

$1B+
Funds under advice
2,000+
Investors under advice
1:1
Your own share advisor
  • ✓
    Investment thesis - why our analysts believe each stock could outperform
  • ✓
    Company overview - what they do, their projects and their outlook
  • ✓
    Fundamentals - valuation metrics, financial health and operating performance
  • ✓
    Financial statements - revenue, profit trends and balance sheet strength
Download the free pharmaceutical stocks report
✓ 100% free report
✓ Instant delivery
✓ No card required
✓ Compiled by our analysts

Investing in ASX pharmaceutical stocks

ASX pharmaceutical stocks give investors exposure to a sector of robust demand, driven by an ageing population, rising rates of chronic disease, and resilience across economic cycles.

ASX pharma stocks include companies operating across a broad value chain, developing, manufacturing, marketing and distributing medicines, as well as providing wholesale distribution and pharmacy retail. They include providers of branded medicines with patent protection and high margins, as well as generic medications that operate on a low-margin, high-volume model. Unlike biotech companies in clinical trial and approval stages, pharmaceutical companies have established revenue streams from approved medications.

In addition to strong, growing demand, this sector is bolstered by the Australian government’s strategic focus on shoring up local medicine supply and development. However, pharmaceutical stocks still face risks including regulatory changes, patent expiry, competition and pricing pressure.

Download our free Pharmaceutical Stocks ASX report to learn more about the sector and pharmaceutical stocks to watch.

Why ASX pharmaceutical stocks are gaining attention

The Australian pharmaceuticals sector is generally considered a defensive investment. Australia’s population is ageing and experiencing rising rates of chronic disease, and the demand for pharmaceuticals remains across economic cycles. This is also the case overseas, and Australian companies selling approved products to the US and other markets face opportunities for growth.

In the wake of COVID-19, which highlighted Australia’s reliance on overseas medicine supplies, the federal government has focused on building up the local supply chain. This includes introducing minimum stockholding requirements for some PBS medicines, and providing support for domestic manufacturing capabilities.

While these factors drive interest in Australian pharmaceutical stocks, it is important to also note the existence of risks arising from pricing pressure, patent expiry, competition and regulatory change.

Download the report →
Medicines on pharmacy shelves

Top pharmaceutical stocks ASX to watch

ASX pharma stocks include companies focused on medicine development, manufacture and distribution, along with pharmacy groups. Some companies operate across multiple areas.

The following pharmaceutical stocks are a representative sample of this spectrum, and while they are not investment recommendations, they may warrant further research. Investors should always consider how any stock will fit with their individual investment goals and broader investment portfolio.

CSL Limited (ASX: CSL)

Key activities: Develops, manufactures and sells plasma-derived medicines, specialty therapies and vaccines - including immunoglobulins Privigen and Hizentra, influenza vaccines Fluad and Flucelvax, along with Ferinject for iron deficiency and kidney disease.

‍
Why watch: Spans much of the pharmaceutical value chain and has a large portfolio of established medicines targeting varying health issues; scale and specialised manufacturing capabilities provide competitive advantage.

Sigma Healthcare Limited (ASX: SIG)

Key activities: Provides wholesale pharmaceutical distribution to community pharmacies across Australia, and operates a large pharmacy network through its retail and franchise brands, including Chemist Warehouse, Amcal and Discount Drug Stores.

‍
Why watch: Earnings are driven by large-scale high-volume medicine distribution and pharmacy sales across a growing network of retail and franchise outlets; potential to improve profitability through expansion and integration.

Medical Developments International Limited (ASX: MVP)

Key activities: Develops, manufactures and sells non-opioid painkiller Penthrox, which is manufactured in Victoria, used in Australian emergency departments, and sold overseas. Also supplies respiratory products such as nebulisers, spacers and masks for asthma and COPD.

‍
Why watch: Penthrox is an established commercial product with sales across more than 20 markets; growth opportunities through expanded Australian hospital use and international sales.

AFT Pharmaceuticals Limited (ASX: AFP)

Key activities: Develops, markets and distributes a broad range of branded, proprietary, licensed and generic medicines, selling through prescription, over-the-counter and hospital channels. Products include the Maxigesic range of pain-relief medicines, eye care, cold and flu, skin care and digestive health.

‍
Why watch: Diversified medicine portfolio sold across Australia, New Zealand and a growing number of international markets; additional growth opportunities via new product development.

Mayne Pharma Group Limited (ASX: MYX)

Key activities: Specialty pharmaceutical manufacturer and distributor. Products include Nexstellis, Bijuva and Imvexxy in women’s health, and Twyneo, Epsolay and Rhofade for dermatology. Operates pharmaceutical manufacturing in Australia and the DistributeRx direct-to-patient prescription distribution platform in the US.

‍
Why watch:
Operates both manufacturing and distribution arms; portfolio of medications, including branded medicines in women’s health with longer patent protection.

IDT Australia Limited (ASX: IDT)

Key activities: Contract development and manufacturing organisation making medicines and pharmaceutical ingredients for other companies. Services cover formulation, testing, manufacturing, packaging and distribution. Advanced Therapies arm specialises in sterile injectable medicines, mRNA products and radiopharmaceuticals.

‍
Why watch: Growing demand for outsourced pharmaceutical manufacturing; higher-value Advanced Therapies business is an important growth area.

Company details and operating status are current as of November 2026.

Hear from our clients

Understanding the pharmaceutical value chain

Pharmaceutical stocks on the ASX include companies operating across medicine development, manufacture, distribution and retail. There is further differentiation between producers of branded products with patent protection and generic product producers. To assess the outlook for individual pharma stocks, it is important to understand the different drivers of profit and risk faced by these different parts of the value chain.

Branded and specialty medicine companies: Sell their own branded medicines, often for specific medical conditions. Patent protection can allow for high margins and pricing power, but this can change rapidly once patents expire and generic competitors may enter the market.

Generic medicine makers: Sell medicines containing the same active ingredient as an original product once the patent has expired. Tend to operate on a low-margin, high-volume basis, with key risks being competition, PBS price reductions or supply problems.

Contract and local manufacturers: Manufacture medicines for themselves or other pharmaceutical companies. Performance depends on production volumes, efficiency and costs, and risks include rising costs, supply shortages, and customer loss.

Wholesale distributors and pharmacy groups: Distributors buy, store and deliver medicines to others, generally operating on high volumes and low margins. Pharmacy groups earn revenue from dispensing medicines and other related products and services. Risks include competition, cost pressures and changes to government pricing or pharmacy arrangements.

The role of the Pharmaceutical Benefits Scheme (PBS) in Australia is also an important consideration. When the Australian government lists medicines on the scheme, they agree to subsidise the price to consumers. This can greatly expand demand for the product, but can also restrict pricing freedom. Changes to PBS listings can have a follow-on impact on revenue and profitability.

Download the report →
Medicine manufacturing line

How Sharewise helps you choose the best pharmaceutical stocks

Research, advisory, execution and corporate finance under one roof — with every recommendation backed by in-house analysis from our Chief Investment Officer, Rabih Ahmed, and his equity research team.

Buy & Sell Recommendations

Every call is grounded in company fundamentals and technical analysis, with a stated thesis and defined entry and exit levels - so you know what you're buying and when to act.

Dedicated Share Advisor

Every client gets their own share advisor — a licensed professional who knows your holdings, tracks the market daily, speaks with our analysts every day, and is reachable during market hours and beyond.

Explore Share Advisory →

Execution & Risk Management

Professional trading technology across ASX, US and global markets. Stop losses, take-profits and position sizing are set at entry, and every trade is executed only on your approval.

How execution works →

Institutional Research

Institutional-grade coverage of ASX small and mid-cap companies across healthcare, resources, technology and energy - stocks most retail research never reaches.

Access the research →

Events & Webinars

In-person events and webinars featuring ASX-listed companies, where you can meet management and put your questions to them directly.

Explore the Investor Hub →

Corporate Finance

Access to placements, IPOs and capital raisings through our corporate finance desk.

Explore Corporate Finance →

How to analyse pharmaceutical stocks before investing

When investing in pharma stocks, look for strong performance and industry position today, as well as the ability to maintain earnings in the future.  Pharmaceutical companies will be generating revenue - unlike many biotech stocks - so standard measures such as P/E ratios and dividend history can be useful. In addition, the following factors specific to the pharmaceutical industry can also be considered:

Product Portfolio and Diversification: Is the company reliant on a single medicine? A lack of diversification means companies are more exposed if sales fall, competition increases, or the product loses market exclusivity.

Patent Expiry and Competition: Are there patents or other market protections in place, and when do they expire? The arrival of generic competitors can lead to sharp falls in prices and market share.

PBS and Overseas Pricing: Having medication included in Australia’s Pharmaceutical Benefits Scheme can potentially broaden demand but restrict pricing. For companies operating overseas, consider local pricing, currency and reimbursement implications.

Product Pipeline: Established medicines eventually face competition, price reductions or declining demand. Is there a pipeline of new product development to replace revenue from ageing products, and what is the timeline?

Profit Margins and Earnings: Examine gross and net profit margins and likely future earnings. Note that branded or specialty medicines can have different economics from high-volume, lower-margin generic medicines and manufacturing or pharmaceutical distribution.

Manufacturing and Regulatory Record: Have there been any issues meeting regulatory requirements? Product recalls, manufacturing problems, regulator warnings or quality issues can impact sales, costs, and reputation.

Debt and Financial Strength: Do debt levels, interest costs and cash flow suggest an ability to meet debt obligations, particularly if earnings come under pressure?

To help research pharmaceutical stocks on the ASX and ensure you’re investing based on sound analysis, download our free report or speak to an expert ASX share advisor.

Download the report →
	Share market charts on a screen

What to expect as a Sharewise client

From your first strategy session to ongoing advice and trade execution, here's what working with Sharewise looks like at every stage.

1

Join Sharewise

Become a member and get full access to our research, advisory and support - with clarity on exactly what's included from day one.

2

Open or transfer your account

Start fresh or transfer an existing portfolio across - individual, joint, SMSF, company or trust, with access to ASX, US and global markets.

3

Access the client portal

Your central hub: view your portfolio and open positions, read our research and market updates, and see every recommendation — on desktop or mobile, 24/7.

4

Strategy session

Sit down with your share advisor to walk through how Sharewise works and how we can support your investing with research-backed guidance grounded in fundamental and technical analysis.

5

Ongoing advice and execution

Your advisor brings you opportunities across ASX and international markets as they arise, and trades are executed only on your approval.

6

Corporate finance opportunities

As a client, you may be eligible for placements, IPOs and capital raisings sourced through our corporate finance desk.

Download the report →

Risks of investing in ASX pharmaceutical stocks

ASX pharma stocks can offer exposure to a defensive investment sector underpinned by ongoing healthcare demand, but they are not without risk. Before purchasing stocks, investors should ensure they understand the risks inherent to the pharmaceutical industry.

Patent expiry and generic competition: When patent protection expires, generic competitors can enter the market and put pressure on prices. This can result in sharp share price falls, even for well-established players.

PBS and overseas price cuts: Government decisions can affect the price and profitability of medicines supplied through the PBS in Australia, or through negotiated prices or reimbursement arrangements overseas.

Manufacturing and regulatory problems: Costs, profits, reputation and share prices can all be impacted if there are manufacturing failures, product recalls or regulatory warnings.

Product concentration: Companies that rely on one or a few medicines are more exposed to changes in demand, competition, pricing or regulatory status.

Legal claims: Pharmaceutical companies can face lawsuits relating to products, patents or alleged harm to patients. These claims, and any subsequent settlements, can affect both earnings and investor confidence.

Currency movements: Exchange rate movements can affect the profits of companies that earn revenue or have elements of their supply chain based overseas.

Trade policy: Changes to trade policy, such as an increase in tariffs, can have a direct impact on companies buying or selling medications across borders, or whose supply chains are affected.

These risks can be managed, but not eliminated, through diversification across companies, across the pharmaceutical supply chain, and across broader investment types. Research on individual pharma company stocks will also help investors understand the risks most relevant to each particular company.

Download the report →
Medicine blister packs

Tips for investing in pharmaceutical stocks

When investing in pharmaceutical company stocks, manage risk by keeping these tips in mind:

Diversify: Spread exposure across several companies and across different areas of the pharmaceutical value chain.

Portfolio balance: Established pharmaceutical companies can play a defensive role within a broader healthcare allocation and may provide a useful counter-balance against higher-risk stocks such as biotechs.

Take a long-term view: Focus on factors that indicate promising long-term performance, such as product diversification and pipelines, patent timelines and debt position, rather than trading solely on regulatory approval or pricing headlines.

To help ensure you’re investing based on quality analysis, download our free report and speak to a specialist ASX share advisor.

Download the report →
Assorted capsules and tablets

Frequently asked questions.

What are pharmaceutical stocks on the ASX?

Pharmaceutical stocks (ASX) are companies listed on the Australian stock exchange that are involved in the manufacture and distribution of medicines. This can include branded and specialty medicine companies, generic medicine makers, contract and local manufacturers, wholesale distributors and pharmacy groups, and they may operate within the Australian market and overseas.

How does the PBS affect ASX pharmaceutical stocks?

The PBS (Pharmaceutical Benefits Scheme) is an Australian government scheme that subsidises a list of prescription medicines in Australia. When a pharmaceutical company has a medicine listed on the PBS, this can potentially increase sales volumes and may positively affect the share price. Conversely, government pricing decisions and PBS price reductions can put pressure on the company’s revenue and margins.

What happens to a pharmaceutical stock when a drug patent expires?

When a drug patent expires, competitors are allowed to produce a generic version of the drug, which can lead to a ‘patent cliff’ of sharply lower prices and reduced market share. This can have a marked impact on the company’s share price, particularly if their business is heavily reliant on the sale of that drug.

Are pharmaceutical stocks a good investment?

Pharmaceutical stocks can provide exposure to a resilient sector that is underpinned by ongoing healthcare demand. As with all stock investments, the sector comes with risks, and returns depend on factors such as competition, patent protection, PBS listing and regulation. Investors should assess each company’s financial position, medicine portfolio and future growth prospects.

Do ASX pharmaceutical stocks pay dividends?

Some pharmaceutical stocks on the ASX pay dividends, particularly those with well-established revenue streams and strong cash flow. Others prioritise reinvesting profits into new products or expansion. Investors should check the dividend policies and payment history of individual pharma stocks before investing.

How do I invest in pharmaceutical stocks in Australia?

You can buy pharmaceutical stocks in Australia through a share trading platform or stockbroker that allows purchasing from the ASX. Speak to an ASX share advisor to find out more.

Get the free pharmaceutical stocks ASX report.

Obtain specific ASX pharmaceutical stock insights and detailed performance analysis for players operating across the pharmaceutical value chain.

Download the report →